{
    "ticker": "STOK",
    "name": "Stoke Therapeutics, Inc.",
    "description": "Stoke Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for genetic diseases. Founded in 2018, Stoke is at the forefront of RNA-targeted drug development, utilizing its proprietary platform to design and create medicines that address the underlying causes of diseases. The company's lead program targets the treatment of Dravet syndrome, a severe form of epilepsy caused by genetic mutations. Stoke's approach aims to enhance the expression of specific proteins that are deficient in patients, providing a novel therapeutic strategy that could significantly improve patient outcomes. With a strong commitment to scientific excellence and patient-centric innovation, Stoke is dedicated to advancing its pipeline while collaborating with leading researchers and institutions. The company's vision is to transform the treatment landscape for patients with genetic diseases and to provide hope for families affected by these conditions.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Wilmington, Massachusetts, USA",
    "founded": "2018",
    "website": "https://www.stoketherapeutics.com",
    "ceo": "Edward M. Kaye",
    "social_media": {
        "twitter": "https://twitter.com/stoketherapeutics",
        "linkedin": "https://www.linkedin.com/company/stoke-therapeutics"
    },
    "investor_relations": "https://investors.stoketherapeutics.com",
    "key_executives": [
        {
            "name": "Edward M. Kaye",
            "position": "CEO"
        },
        {
            "name": "Robert C. G. DeWitt",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "STK-001"
            ]
        }
    ],
    "seo": {
        "meta_title": "Stoke Therapeutics, Inc. | Innovating Genetic Disease Therapies",
        "meta_description": "Explore Stoke Therapeutics, Inc., a biotechnology company developing RNA-targeted therapies for genetic diseases like Dravet syndrome. Learn about their innovative approach and pipeline.",
        "keywords": [
            "Stoke Therapeutics",
            "Biotechnology",
            "RNA-targeted therapies",
            "Dravet syndrome",
            "Genetic diseases"
        ]
    },
    "faq": [
        {
            "question": "What is Stoke Therapeutics known for?",
            "answer": "Stoke Therapeutics is known for developing RNA-targeted therapies for genetic diseases."
        },
        {
            "question": "Who is the CEO of Stoke Therapeutics?",
            "answer": "Edward M. Kaye is the CEO of Stoke Therapeutics, Inc."
        },
        {
            "question": "Where is Stoke Therapeutics headquartered?",
            "answer": "Stoke Therapeutics is headquartered in Wilmington, Massachusetts, USA."
        },
        {
            "question": "What is the lead product of Stoke Therapeutics?",
            "answer": "Stoke's lead product is STK-001, aimed at treating Dravet syndrome."
        },
        {
            "question": "When was Stoke Therapeutics founded?",
            "answer": "Stoke Therapeutics was founded in 2018."
        }
    ],
    "competitors": [
        "IONQ",
        "SRPT",
        "CRSP",
        "EDIT"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "VRTX"
    ]
}